Amplia Therapeutics INNMF Stock
Amplia Therapeutics Price Chart
Amplia Therapeutics INNMF Financial and Trading Overview
| Amplia Therapeutics stock price | 0.1 USD |
| Previous Close | 0.1 USD |
| Open | 0.1 USD |
| Bid | 0.1 USD x 2000000 |
| Ask | 0.11 USD x 22000000 |
| Day's Range | 0.1 - 0.1 USD |
| 52 Week Range | 0.04 - 0.27 USD |
| Volume | 10K USD |
| Avg. Volume | 33.95K USD |
| Market Cap | 51.31M USD |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.01 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
INNMF Valuation Measures
| Enterprise Value | 23.83M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 9.345002 |
| Price/Book (mrq) | 1.6455542 |
| Enterprise Value/Revenue | 4.341 |
| Enterprise Value/EBITDA | -3.105 |
Trading Information
Amplia Therapeutics Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 156.41% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.27 USD |
| 52 Week Low | 0.04 USD |
| 50-Day Moving Average | 0.13 USD |
| 200-Day Moving Average | 0.1 USD |
INNMF Share Statistics
| Avg. Volume (3 month) | 33.95K USD |
| Avg. Daily Volume (10-Days) | 99.04K USD |
| Shares Outstanding | 513.07M |
| Float | 434.87M |
| Short Ratio | N/A |
| % Held by Insiders | 15.22% |
| % Held by Institutions | 18.92% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2026 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | March 31, 2027 |
Profitability
| Profit Margin | -140.37% |
| Operating Margin (ttm) | -115.85% |
| Gross Margin | 92.97% |
| EBITDA Margin | -139.81% |
Management Effectiveness
| Return on Assets (ttm) | -14.93% |
| Return on Equity (ttm) | -25.47% |
Income Statement
| Revenue (ttm) | 5.49M USD |
| Revenue Per Share (ttm) | 0.01 USD |
| Quarterly Revenue Growth (yoy) | 7.79% |
| Gross Profit (ttm) | 5.1M USD |
| EBITDA | -7676155 USD |
| Net Income Avi to Common (ttm) | -7707152 USD |
| Diluted EPS (ttm) | -0.01 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 27.85M USD |
| Total Cash Per Share (mrq) | 0.05 USD |
| Total Debt (mrq) | 341.11K USD |
| Total Debt/Equity (mrq) | 0.86 USD |
| Current Ratio (mrq) | 19.781 |
| Book Value Per Share (mrq) | 0.0607698 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -8733504 USD |
| Levered Free Cash Flow (ttm) | -6045307 USD |
Profile of Amplia Therapeutics
| Country | United States |
| State | VIC |
| City | Melbourne |
| Address | 90 William Street |
| ZIP | 3000 |
| Phone | 61 3 9123 1140 |
| Website | https://www.ampliatx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | N/A |
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Q&A For Amplia Therapeutics Stock
What is a current INNMF stock price?
Amplia Therapeutics INNMF stock price today per share is 0.1 USD.
How to purchase Amplia Therapeutics stock?
You can buy INNMF shares on the OTC Markets OTCPK exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Amplia Therapeutics?
The stock symbol or ticker of Amplia Therapeutics is INNMF.
Which industry does the Amplia Therapeutics company belong to?
The Amplia Therapeutics industry is Biotechnology.
How many shares does Amplia Therapeutics have in circulation?
The max supply of Amplia Therapeutics shares is 513.31M.
What is Amplia Therapeutics Price to Earnings Ratio (PE Ratio)?
Amplia Therapeutics PE Ratio is now.
What was Amplia Therapeutics earnings per share over the trailing 12 months (TTM)?
Amplia Therapeutics EPS is -0.01 USD over the trailing 12 months.
Which sector does the Amplia Therapeutics company belong to?
The Amplia Therapeutics sector is Healthcare.